| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PUMA |
| Uniprot No | Q9BXH1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-193aa |
| 氨基酸序列 | MARARQEGSSPEPVEGLARDGPRPFPLGRLVPSAVSCGLCEPGLAAAPAAPTLLPAAYLCAPTAPPAVTAALGGSRWPGGPRSRPRGPRPDGPQPSLSLAEQHLESPVPSAPGALAGGPTQAAPGVRGEEEQWAREIGAQLRRMADDLNAQYERRRQEEQQRHRPSPWRVLYNLIMGLLPLPRGHRAPEMEPN |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3-4条关于PUMA重组蛋白的参考文献示例(注：文献信息为模拟示例，仅供参考)：
---
1. **文献名称**: *"Recombinant PUMA Induces Apoptosis via Mitochondrial Pathway in Cancer Cells"*
**作者**: Chen L. et al.
**摘要**: 研究报道了通过大肠杆菌系统表达重组PUMA蛋白，并证明其通过激活线粒体凋亡通路，在多种癌细胞中诱导caspase依赖性细胞死亡。
2. **文献名称**: *"Structural Characterization of PUMA Protein and Its Interaction with Bcl-2 Family Members"*
**作者**: Kim S. et al.
**摘要**: 利用重组PUMA蛋白进行结构解析，揭示了其α-螺旋结构域与抗凋亡蛋白Bcl-xL的结合机制，为靶向药物设计提供依据。
3. **文献名称**: *"PUMA Recombinant Protein Enhances Radiotherapy Sensitivity in Glioblastoma Models"*
**作者**: Wang Y. et al.
**摘要**: 在胶质母细胞瘤模型中，重组PUMA蛋白联合放疗显著促进肿瘤细胞凋亡，表明其在协同治疗中的潜在应用。
4. **文献名称**: *"High-Yield Production of Soluble PUMA in HEK293 Cells for Functional Studies"*
**作者**: Johnson R. et al.
**摘要**: 开发了一种基于哺乳动物细胞(HEK293)的重组PUMA蛋白高效表达与纯化方法，验证了其与Mcl-1蛋白的相互作用及促凋亡活性。
---
**提示**：实际文献需通过学术数据库(如PubMed、Web of Science)检索关键词“PUMA recombinant protein”、“PUMA apoptosis”等获取。推荐结合具体研究方向筛选实验方法学或机制研究类论文。
PUMA (p53 Upregulated Modulator of Apoptosis) is a pro-apoptotic protein critical in regulating programmed cell death. Discovered in 2001. it belongs to the BH3-only subgroup of the BCL-2 protein family, which governs mitochondrial apoptosis. PUMA is transcriptionally activated by p53 under stress conditions like DNA damage, hypoxia, or oncogene activation, though p53-independent pathways also exist. Its primary role involves neutralizing anti-apoptotic BCL-2 proteins (e.g., BCL-2. BCL-xL), enabling activation of pro-apoptotic effectors BAX/BAK to trigger cytochrome c release and caspase cascade activation.
Recombinant PUMA proteins are engineered versions produced via bacterial, mammalian, or insect cell expression systems. These proteins typically retain the conserved BH3 domain essential for interacting with BCL-2 family members. Researchers utilize recombinant PUMA to study apoptosis mechanisms, screen small-molecule apoptosis inducers, or develop cancer therapies aiming to restore apoptotic pathways in resistant tumors. For instance, PUMA-based gene therapy or BH3 mimetics are explored to sensitize cancer cells to chemo/radiotherapy.
Challenges in handling PUMA include its intrinsic disorder and aggregation propensity. Modified variants (e.g., solubility-tagged or truncated forms) are often designed to enhance stability and experimental utility. Current research focuses on optimizing delivery systems (nanoparticles, viral vectors) and combination strategies to leverage PUMA's tumor-suppressive potential while minimizing off-target effects. As a key apoptosis mediator, PUMA remains a focal point for understanding cell death regulation and developing targeted cancer therapeutics.
×
